Company Description
Lirum Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities.
Our lead product candidate, LX-101, is a novel, clinical stage, next generation, precision-engineered targeted therapy directed to the IGF-1R.
The IGF-1/IGF-1R pathway has been implicated in a host of diseases. LX-101 has been clinically evaluated by the licensor in Phase 1a trials of patients with advanced, pretreated cancer, where it was found to be well-tolerated and demonstrated single agent activity.
We are developing LX-101 in certain oncology and autoimmune indications and we are seeking to establish LX-101 as the standard of care for treating these diseases.
| Country | United States |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Peter McDonald |
Contact Details
Address: 590 Madison Ave, 21st Floor New York, NY 10022 United States | |
| Phone | (646) 964-1402 |
| Website | lirumtx.com |
Stock Details
| Ticker Symbol | LRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001965411 |
| Employer ID | 88-1228824 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter McDonald | Chief Executive Officer, Interim Principal Financial and Accounting Officer |
| Ivan Bergstein | Chairman |
| Kenneth Hoberman | Vice-Chairman |
| Mark Sard | Director |
| Daniel Hume | Director |
| Alan Forman | Director |
| Ken Zuerblis | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | FWP | Free Writing Prospectus |
| Jun 28, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 18, 2024 | FWP | Free Writing Prospectus |
| Apr 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 22, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 2, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 20, 2023 | DRS | [Cover] Draft Registration Statement |
| Feb 23, 2023 | D | Notice of Exempt Offering of Securities |